Cai-yong Yu

Learn More
In a previous study, we generated two monoclonal antibodies (mAbs) in mice, aNogoA-N and aNogo-66 mAb, which were raised against recombinant N-terminal fragments of rat NogoA and Nogo-66, respectively. When compared with the commercial rabbit anti-rat NogoA polyclonal antibody (pAb), which can specifically recognise NogoA, the two mAbs were also specific(More)
MicroRNA-124 (miR-124) is abundantly expressed in neurons in the mammalian central nervous system, and plays critical roles in the regulation of gene expression during embryonic neurogenesis and postnatal neural differentiation. However, the expression profile of miR-124 after spinal cord injury and the underlying regulatory mechanisms are not well(More)
AIM To detect and characterize of 6 monoclonal antibodies (mAbs) against different epitopes of rat Nogo-A molecule in immunohistochemistry to decide their applications in futrue. Four mAbs against Nogo66 fragment are named Nogo66-1, Nogo66-2, Nogo66-3 and Nogo66-4. The rest of 2 mAbs against N-termial 570-691aa fragment are named NogoN-1 and NogoN-2. (More)
AIM To analysis the role of T lymphocytes in spinal cord regeneration by comparing the recovery of movement and the morphological changes of injury area between BALB/c and DO11.10 transgenic mice. METHODS Producing a crush injury model of spinal cord with special forceps. Analyze the changes of spinal cord injury area with H&E and GFAP, CD11b and(More)
AIM To establish a ubiquitously expressed PD-L1 transgenic mouse model and evaluate its recovery of motor function after spinal cord injury. METHODS Clone and sequence the complete mouse PD-L1 cDNA and construct the pCAG-PD-L1 transgenic vector by inserting the PD-L1 cDNA into the pCAGGS vector. The PD-L1 transgenic (TgPD-L1) mice were established by(More)
  • 1